Clinical Trial Update: Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of ELIGARD 22.5 mg in prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ELIGARD 22.5mg (leuprolide acetate)

Snippet

Sponsor: HanAll BioPharma Co., Ltd. | Conditions: Prostate Cancer | Phase 4 | Status: COMPLETED